Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non – Small Cell Lung Cancer

PURPOSE: TRIBUTE was a phase III trial evaluating the addition of erlotinib to carboplatin and paclitaxel as a first-line treatment for advanced non – small cell lung cancer that did not meet its primary end point of improving overall survival. Here, we assess the value of using epidermal growth fac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hirsch, Fred R., Varella-Garcia, Marileila, Dziadziuszko, Rafal, Xiao, Yun, Gajapathy, Sujatha, Skokan, Margaret, Lin, Ming, O’Neill, Vincent, Bunn, Paul A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3368373/
https://ncbi.nlm.nih.gov/pubmed/18829515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0539
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados